|
|
|
|
|
Epinastine
drug data and news
Epinastine drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Epinastine | ||
| Brand Names/Synonyms | CHEMBANK1621; Elestat; Epinastina [Spanish]; Epinastine; Epinastine [Inn]; Epinastinum [Latin]; WAL 801 | ||
| Indication | For the prevention of itching associated with allergic conjunctivitis. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Epinastine is an antihistamine and an inhibitor of histamine release from the mast cell for topical administration to the eyes. Epinastine is indicated for the prevention of itching associated with allergic conjunctivitis. Epinastine is a topically active, direct H1-receptor antagonist and an inhibitor of the release of histamine from the mast cell. Epinastine is selective for the histamine H1-receptor and has affinity for the histamine H2 receptor. Epinastine also possesses affinity for the a1-, a2-, and 5-HT2 -receptors. Epinastine does not penetrate the blood/brain barrier and, therefore, is not expected to induce side effects of the central nervous system. | ||
| Mechanism Of Action | Epinastine has a multiaction effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding to both the H1- and H2-receptors to stop itching and provide lasting protection, and 3. prevents the release of proinflammatory chemical mediators from the blood vessel to halt progression of the allergic response. | ||
| Epinastine News (When available) |
Inspire acquires rights to Boehringer's epinastine Feb 22, 2006 Inspire Announces Development and License Agreement with ... Feb 21, 2006 Inspire buys US rights to allergy drug Feb 21, 2006 Inspire to Present at 26th Annual Cowen Health Care Conference Feb 28, 2006 Inspire Reports Fourth Quarter and Full Year 2005 Financial ... Feb 28, 2006 Inspire Licenses Drug Development Deal With German Firm Feb 21, 2006 Inspire buys rights to nasal spray Feb 22, 2006 | ||
| Dosage Forms | Not Available | ||
| Drug_Category | Antihistamines; Ophthalmics; ATC:R06AX24; ATC:S01GX10 | ||
| Absorption | The absolute bioavailability of epinastine is about 40%. | ||
| Interactions |
Interactions for Epinastine: None Reported | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Not Available | ||
| Chemical Formula | C16H15N3 | ||
| Molecular Weight | 249.311 g/mol | ||
| Smiles String | C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N | ||
| Melting Point | 205 - 208 °C | ||
| Water Solubility | Not Available | ||
| State | White to yellowish white powder | ||
| LogP/Hphobicity | 2.969 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 12 hours | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Epinastine.html http://www.rxlist.com/cgi/generic3/elestat.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00043 | ||
| CAS Registry Number | 80012-43-7 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:213455 | ||
| PharmGKB ID | PA10070 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |